Beta-blocker therapy does not alter the rate of aortic root dilation in pediatric patients with Marfan syndrome JOURNAL OF PEDIATRICS Tierney, E. S., Feingold, B., Printz, B. F., Park, S. C., Graham, D., Kleinman, C. S., Mahnke, C. B., Timchak, D. M., Neches, W. H., Gersony, W. M. 2007; 150 (1): 77-82

Abstract

To test the hypothesis that chronic beta-blocker therapy in pediatric patients with Marfan syndrome alters the rate of aortic root dilation. Beta-blockade has been advocated as preventive therapy for Marfan syndrome based on reports indicating a decreased rate of aortic root dilation in treated patients.Patients with Marfan syndrome (n = 63) followed at Children's Hospital of Pittsburgh or Children's Hospital of New York-Presbyterian who had > or =18 months of echocardiographic follow-up were studied. All clinical data and 213 serial echocardiograms were reviewed, and aortic root dimensions were measured. Patients were divided into 2 groups for comparison: untreated (n = 34) and treated (n = 29).At study entry, the 2 study groups were comparable in terms of age, sex, body surface area (BSA), aortic root measurements, heart rate, and corresponding z scores. Follow-up duration in each group was similar. At last follow-up, heart rates and heart rate z scores were lower in the treated group. Rates of change of aortic root measurements (P = .52) and the corresponding z scores were not statistically different between the 2 group at the study's end.This study suggests that that beta-blocker therapy does not significantly alter the rate of aortic root dilation in children with Marfan syndrome. Based on these data, the recommendation of lifetime beta-blocker therapy instituted during childhood should be reassessed.

View details for DOI 10.1016/j.jpeds.2006.09.003

View details for Web of Science ID 000243450500018

View details for PubMedID 17188619